{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:01:13Z","timestamp":1791385273547,"version":"4.3.3"},"reference-count":78,"publisher":"Royal College of Psychiatrists","issue":"2","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":9467,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1992,2]]},"abstract":"<jats:p>The Cross-National Collaborative Panic Study, Phase Two, compared alprazolam with imipramine and with placebo in a sample of 1168 randomly assigned subjects. The study, conducted at 12 centres, assessed clinical change over eight weeks of double-blind drug treatment. Improvement occurred with alprazolam by week 1 and 2, and with imipramine by week 4. By the end of week 8, however, the effects of the two active drugs were similar to each other, and both were superior to placebo for most outcome measures.<\/jats:p>","DOI":"10.1192\/bjp.160.2.191","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T04:56:07Z","timestamp":1224046567000},"page":"191-202","source":"Crossref","is-referenced-by-count":167,"title":["Drug Treatment of Panic Disorder: Comparative Efficacy of Alprazolam, Imipramine, and Placebo"],"prefix":"10.1192","volume":"160","author":[{"given":"Gerald L.","family":"Klerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000035571_ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198610023151403"},{"key":"S0007125000035571_ref58","first-page":"835","article-title":"An update on treatment of the anxiety disorders","volume":"38","author":"Roy-Byrne","year":"1987","journal-title":"Hospital and Community Psychiatry"},{"key":"S0007125000035571_ref43","volume-title":"La Angusta Vital","author":"Lopez-Ibor","year":"1950"},{"key":"S0007125000035571_ref26","first-page":"88","volume-title":"Annual Review of Psychiatry","volume":"vol. 7","author":"Fyer","year":"1988"},{"key":"S0007125000035571_ref2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1980"},{"key":"S0007125000035571_ref34","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800290021003"},{"key":"S0007125000035571_ref52","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800290037005"},{"key":"S0007125000035571_ref59","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(82)90103-4"},{"key":"S0007125000035571_ref17","first-page":"580","article-title":"Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone","volume":"47","author":"Charney","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000035571_ref55","article-title":"New uses for clonazepam in psychiatry","volume":"48","author":"Rosenbaum","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000035571_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(86)90015-7"},{"key":"S0007125000035571_ref33","first-page":"235","volume-title":"Anxiety: New Research and Changing Concepts","author":"Klein","year":"1981"},{"key":"S0007125000035571_ref65","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(88)90214-6"},{"key":"S0007125000035571_ref30","first-page":"49","article-title":"Overview of the clinical studies program. NIMH Collaborative Program on Psychobiology of Depression","volume":"136","author":"Katz","year":"1979","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000035571_ref4","first-page":"42","article-title":"Clomipramine (Anafranil) and behavior therapy in obsessive-compulsive and phobic disorders","volume":"5","author":"Amin","year":"1977","journal-title":"Journal of Internal Medical Research"},{"key":"S0007125000035571_ref16","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1985.01790280055005"},{"key":"S0007125000035571_ref37","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/archpsyc.1989.01810070096016","article-title":"The efficacy of alprazolam in panic disorder and agoraphobia: a critique of recent reports (letter)","volume":"46","author":"Klerman","year":"1989","journal-title":"Archives of General Psychiatry"},{"key":"S0007125000035571_ref71","first-page":"991","article-title":"Classification of anxiety disorders","volume":"11","author":"Tyrer","year":"1986","journal-title":"Journal of Anxiety Disorders"},{"key":"S0007125000035571_ref21","first-page":"121","article-title":"Patients with panic disorder unaccompanied by depression improved with alprazolam and imipramine treatment","volume":"52","author":"Deltito","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000035571_ref73","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(89)90009-8"},{"key":"S0007125000035571_ref32","doi-asserted-by":"publisher","DOI":"10.1007\/BF02193476"},{"key":"S0007125000035571_ref5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1192\/bjp.150.4.557","article-title":"Consensus statement: panic disorder","volume":"150","author":"Ashcroft","year":"1987","journal-title":"British Journal of Psychiatry"},{"key":"S0007125000035571_ref25","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1972.01750200072015"},{"key":"S0007125000035571_ref69","first-page":"16","article-title":"Clonazepam vs. alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial","volume":"48","author":"Tesar","year":"1984","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000035571_ref77","unstructured":"Williams J. & Spitzer R. (1992) SCID\u2013UP reliability. American Journal of Psychiatry (in press)."},{"key":"S0007125000035571_ref7","first-page":"27","article-title":"Pharmacotherapy of the panic disorders","volume":"47","author":"Ballenger","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000035571_ref75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911023211801"},{"key":"S0007125000035571_ref41","first-page":"343","article-title":"SAFTEE: a technique for the systematic assessment of side effects in clinical trials","volume":"22","author":"Levine","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"key":"S0007125000035571_ref42","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198602000-00004"},{"key":"S0007125000035571_ref50","first-page":"1411","volume-title":"Psychopharmacology: A Generation of Progress","author":"McNair","year":"1978"},{"key":"S0007125000035571_ref19","doi-asserted-by":"publisher","DOI":"10.1007\/BF00464571"},{"key":"S0007125000035571_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7916(85)90026-6"},{"key":"S0007125000035571_ref48","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(79)90041-X"},{"key":"S0007125000035571_ref24","first-page":"680","article-title":"Treatment of phobic neurosis with clomipramine: a controlled clinical trial","volume":"20","author":"Escobar","year":"1976","journal-title":"Current Therapeutic Research"},{"key":"S0007125000035571_ref51","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1984.01790140077009"},{"key":"S0007125000035571_ref3","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1987"},{"key":"S0007125000035571_ref78","volume-title":"International Classification of Disease","year":"1988"},{"key":"S0007125000035571_ref1","first-page":"301","article-title":"Alprazolam treatment for panic disorders","volume":"47","author":"Alexander","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000035571_ref6","volume-title":"The Pharmacological Basis of Therapeutics","author":"Baldessarini","year":"1985"},{"key":"S0007125000035571_ref68","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(88)90069-6"},{"key":"S0007125000035571_ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"S0007125000035571_ref72","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(88)90070-2"},{"key":"S0007125000035571_ref22","first-page":"13","article-title":"SCL\u201390: an outpatient psychiatric rating scale: preliminary report","volume":"9","author":"Derogatis","year":"1973","journal-title":"Psychopharmacology Bulletin"},{"key":"S0007125000035571_ref9","volume-title":"Anxiety and its Disorders","author":"Barlow","year":"1988"},{"key":"S0007125000035571_ref38","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(83)90200-9"},{"key":"S0007125000035571_ref31","first-page":"49","article-title":"Treatment of phobic states with antidepressants","volume":"136","author":"Kelley","year":"1970","journal-title":"British Journal of Psychiatry"},{"key":"S0007125000035571_ref14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1176\/ajp.143.4.483","article-title":"Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy","volume":"143","author":"Carr","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000035571_ref44","doi-asserted-by":"crossref","unstructured":"Lydiard R. B. , Lesser I. M. , Ballenger J. C. , et al (1992) A fixed dose study of 2 mg alprazolam, 6 mg alprazolam and placebo in panic disorder. Journal of Clinical Psychopharmacology (in press).","DOI":"10.1097\/00004714-199204000-00004"},{"key":"S0007125000035571_ref46","volume-title":"Fears, Phobias and Rituals","author":"Marks","year":"1987a"},{"key":"S0007125000035571_ref64","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198302000-00006"},{"key":"S0007125000035571_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(88)90054-7"},{"key":"S0007125000035571_ref54","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800290043006"},{"key":"S0007125000035571_ref23","first-page":"458","article-title":"Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study","volume":"47","author":"Dunner","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000035571_ref27","first-page":"277","article-title":"Panic disorder: fact or fiction? (editorial)","volume":"19","author":"Gelder","year":"1989","journal-title":"Psychology"},{"key":"S0007125000035571_ref40","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800290053007"},{"key":"S0007125000035571_ref36","first-page":"407","article-title":"The design and conduct of the Upjohn Cross-National Collaborative Panic Study","volume":"45","author":"Klerman","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"key":"S0007125000035571_ref29","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"S0007125000035571_ref57","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(88)90068-4"},{"key":"S0007125000035571_ref10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1176\/ajp.141.3.464","article-title":"Bromazepam, another high potency benzodiazepine for panic attacks","volume":"141","author":"Beaudry","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000035571_ref39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198311243092105"},{"key":"S0007125000035571_ref53","first-page":"458","article-title":"Antidepressant properties of the triazolobenzodiazepines, alprazolam and adinazolam: studies on the olfactory bulbectomized rat model of depression","volume":"19","author":"O'Conner","year":"1985","journal-title":"British Journal of Clinical Pharmacology"},{"key":"S0007125000035571_ref62","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1980.01780140053006"},{"key":"S0007125000035571_ref76","doi-asserted-by":"publisher","DOI":"10.1007\/BF02156040"},{"key":"S0007125000035571_ref49","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/archpsyc.1989.01810070094015","article-title":"The efficacy of alprazolam in panic disorder and agoraphobia: a critique of recent reports (letter)","volume":"46","author":"Marks","year":"1989","journal-title":"Archives of General Psychiatry"},{"key":"S0007125000035571_ref35","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(90)90033-M"},{"key":"S0007125000035571_ref45","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810110026004"},{"key":"S0007125000035571_ref60","volume-title":"Annual Review of Psychiatry","author":"Shear","year":"1988"},{"key":"S0007125000035571_ref63","first-page":"235","article-title":"The classification of anxiety and hysterical states","volume":"2","author":"Sheehan","year":"1982","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"S0007125000035571_ref74","volume-title":"Biological Psychiatry: Proceedings from the IVth World Congress of Biological Psychiatry","author":"Versiani","year":"1985"},{"key":"S0007125000035571_ref11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1176\/ajp.142.7.787","article-title":"The diagnostic validity of anxiety disorders and their relationships to depressive illness","volume":"142","author":"Breier","year":"1985","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000035571_ref47","doi-asserted-by":"publisher","DOI":"10.1177\/026988118700100103"},{"key":"S0007125000035571_ref56","first-page":"293","article-title":"The phobic anxiety\u2013depersonalization syndrome and some general aetiological problems in psychiatry","volume":"1","author":"Roth","year":"1959","journal-title":"Journal of Neuropsychiatry"},{"key":"S0007125000035571_ref66","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1978.01770300115013"},{"key":"S0007125000035571_ref61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198207153070304"},{"key":"S0007125000035571_ref18","first-page":"418","article-title":"Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam","volume":"50","author":"Charney","year":"1989","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000035571_ref67","volume-title":"Structured Clinical Interview for DSM\u2013III (SCID)","author":"Spitzer","year":"1983"},{"key":"S0007125000035571_ref70","first-page":"685","article-title":"Neurosis divisible","volume":"i","author":"Tyrer","year":"1984","journal-title":"Lancet"},{"key":"S0007125000035571_ref8","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800290027004"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000035571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T19:07:56Z","timestamp":1558120076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000035571\/type\/journal_article"}},"subtitle":["Cross-National Collaborative Panic Study, Second Phase Investigators"],"short-title":[],"issued":{"date-parts":[[1992,2]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1992,2]]}},"alternative-id":["S0007125000035571"],"URL":"https:\/\/doi.org\/10.1192\/bjp.160.2.191","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,2]]}}}